The test is a biologic signature that uses a panel of seven protein biomarkers COX 2, FOXA1, HER2, Ki 67, p16 INK4A, PgR, and SIAH2, based on work from the University of California, San Francisco, to assess key pathways in the tumor biology in combination with four clinicopathologic factors, including margin status, which together provide an individualized risk assessment <a href=https://propecia.mom>proscar finasteride</a>